Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. - Wikidata - wikimedia - TriplyDB

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

http://www.wikidata.org/entity/Q36912591

about

Optimal primary surgical treatment for advanced epithelial ovarian cancer C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma Wnt5a Signaling in Cancer Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives Disparities in Gynecological Malignancies The Relevance of Gynecologic Oncologists to Provide High-Quality of Care to Women with Gynecological Cancer Selecting the best strategy of treatment in newly diagnosed advanced-stage ovarian cancer patients Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer Tumor infiltrating lymphocytes in ovarian cancer Preservation of ovarian function during chemotherapy and radiotherapy in young women with malignancies Current status and evolution of preclinical drug development models of epithelial ovarian cancer Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.Advanced ovarian cancer: what should be the standard of care?ARID1A gene silencing reduces the sensitivity of ovarian clear cell carcinoma to cisplatin Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182 Role of cytoreductive surgery in recurrent ovarian cancer.Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study.Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study Sensitive β-galactosidase-targeting fluorescence probe for visualizing small peritoneal metastatic tumours in vivo.Differentiation of epithelial ovarian cancer subtypes by use of imaging and clinical data: a detailed analysis.Neoadjuvant chemotherapy or primary surgery for stage III/IV ovarian cancer: contribution of diagnostic laparoscopy HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets.Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas.Wnt5a Signaling in Normal and Cancer Stem Cells Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.Targeting SRC in mucinous ovarian carcinoma.Tumor-associated macrophages contribute to tumor progression in ovarian cancer.Involvement of Chromatin Remodeling Genes and the Rho GTPases RhoB and CDC42 in Ovarian Clear Cell Carcinoma.Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference.Population-based study of ovarian cancer in Côte d'Or: prognostic factors and trends in relative survival rates over the last 20 years.Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites.X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary.Neutrophils in the tumor microenvironment: trying to heal the wound that cannot heal.Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology.HER2-positive mucinous adenocarcinomas of the ovary have an expansile invasive pattern associated with a favorable prognosis

P2860

Q24234923-658FDAF3-3C28-43FF-B836-38DEA7E7E7DE Q24650289-1C3F7D40-6484-472C-9547-C6F1E3198AE8 Q26738408-7B31D64D-4E60-497C-BEFF-F60FBA92DAC9 Q26749280-3F1FAC9F-48A3-4C3E-8C8A-B3DF91A503BD Q26768263-31C4758C-7F09-4C50-9378-38F5DD3C474D Q26770278-A2BE1AF0-FD22-4899-9690-5B06FD9787B3 Q26771731-436CA7E9-4BE3-49C7-8C4D-9D74936CEC06 Q26775315-FD96D3A3-87E8-4385-9AF4-449002557053 Q26783551-7A3B3BFC-AF5C-4867-A40E-5CCC126FAE64 Q27021878-E8896C75-5455-4201-8BC5-28989A5162BC Q27026896-81A76C95-A00A-453E-8F8B-FA9872C635C6 Q27028117-8E4E718F-62D8-445C-9AB2-E8C2906AD1B4 Q27851688-2F6D349B-24FB-4D0D-B4AC-B19DBA551413 Q27852053-009109EC-CC1A-4CA1-95EA-70730CB58BA2 Q28468340-EEE79E47-4AA7-4118-AEDE-D675F1786133 Q30276610-C9B8D68C-1B1F-49C1-B8AE-A13C2F5437A6 Q30359038-35364A04-E41B-44E3-86E8-348639084B08 Q30360249-307BCFF2-161D-4342-AAD3-5C22E6DE4E2D Q30378801-18EA85D1-8D4A-4780-97F9-7B8C406CCBF3 Q30417640-99C14A6B-5E98-46E3-9CAA-43C63B80672F Q30418957-8FC5880C-0235-4ED4-94CD-1C6CD02A5CB5 Q30419554-FFF06445-831A-4DB7-B711-A28CF02632FC Q30634871-F6DAB8FC-9676-4B05-9C84-2E23E29A76B7 Q31044907-DAB291DF-C3B8-4BD2-A88A-BB3DE965BEA9 Q33461909-8C56AC85-07E5-4C35-8844-3FD8ABE69E66 Q33517907-E867023D-449F-4FC6-AA52-468E982176B0 Q33543156-54AF85A8-C2E8-4A1F-87A7-9FACCCD837F9 Q33563929-44F2F8ED-9200-4771-9109-733A14BFBCFA Q33604792-A0C6F8A4-0FEF-47B3-834D-0F0F74953E6E Q33626973-5DA47C12-E6B8-4683-9CE8-5363985365D5 Q33638051-6204717D-F649-4575-9DD9-594889A82B77 Q33718878-5001667F-B05D-41DA-8A1A-02A6FE7095A6 Q33734760-F31B466A-0FAF-4C04-AEE6-8525F6AB6CE7 Q33735170-7B4B9BFA-2173-4821-81B6-3148343E6A62 Q33743627-10A6F82F-B894-4C43-B0EC-4F6DE1490A32 Q33748623-83BB818C-7FA6-4FB9-885F-2E2E408D13AF Q33750177-80B69BAA-F65B-4291-8E61-72A57C656E8D Q33816141-F6A293E0-6AA9-48E2-AF9A-B6AEC373E2E5 Q33837836-09FB1065-5969-4498-A3F9-BA1ABB2D856A Q34029209-77D940BB-4F82-4377-8385-4A6CFA865525

P2860

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

http://www.wikidata.org/entity/Q36912591

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Prognostic factors for stage I ...... ecologic Oncology Group Study.

@en

type

label

Prognostic factors for stage I ...... ecologic Oncology Group Study.

@en

prefLabel

Prognostic factors for stage I ...... ecologic Oncology Group Study.

@en

P1433

Q36912591-C00FE803-7CC6-4881-B059-3410CB5B3B25

P1476

Q36912591-F9565B6E-3BCF-4D00-B62F-974A1543F004

P2093

Q36912591-161E2320-0830-4F31-B886-CC662572CFB8

Q36912591-1D0707BE-FFC8-43E7-A34D-02B3E9CAC7BC

Q36912591-2F1A84D9-492D-4E2A-A025-A81EC11ED72B

Q36912591-4EA9672D-713B-47D8-A6F1-6377C8FCD317

Q36912591-8E147527-5292-470B-A1B1-69A1B12E83C1

Q36912591-93263095-F209-4333-9893-4887C4FAF18F

Q36912591-A686281C-4CFB-4806-82F6-670EC2F6A484

Q36912591-B288568F-BBB2-4E19-B681-52B0C45CA43C

Q36912591-B87A317E-B0BE-4C5C-9304-B8A6EC7ED000

Q36912591-CA10E8BD-5030-43F8-8217-E48BC5C0AF19

P304

Q36912591-B0184068-662D-4D67-B0C3-6FBE4DFCEAE0

P31

Q36912591-888163AB-0FF2-40F6-9BA9-7C5935FB9FA3

P356

Q36912591-589ED0C1-A41F-4685-B6EE-A4397D4A3CF9

P407

Q36912591-B57A1596-548B-49CD-8FBF-2A58E237EFEE

P433

Q36912591-80CD5624-4682-442A-BD15-2E67C14CB403

P478

Q36912591-F3099F6E-E58F-4206-BC79-9F9D8A600412

P50

Q36912591-916B1AB1-99A2-477D-86F7-05DE54173E70

P577

Q36912591-9531C06A-A2D6-4051-B5E8-E9821DB6574D

P698

Q36912591-AFE1E0F8-03BF-48A1-B168-197CCAD2800B

P921

Q36912591-4356A356-7F6A-4D65-8579-B987078A13B1

P356

JCO.2006.10.2517

P1433

Journal of Clinical Oncology

P1476

Prognostic factors for stage I ...... ecologic Oncology Group Study.

@en

P2093

Chunqiao Tian

http://www.w3.org/2001/XMLSchema#string

Deborah K Armstrong

http://www.w3.org/2001/XMLSchema#string

G Larry Maxwell

http://www.w3.org/2001/XMLSchema#string

Gynecologic Oncology Group Study

http://www.w3.org/2001/XMLSchema#string

Jay W Carlson

http://www.w3.org/2001/XMLSchema#string

Maurie Markman

http://www.w3.org/2001/XMLSchema#string

Peter G Rose

http://www.w3.org/2001/XMLSchema#string

Robert F Ozols

http://www.w3.org/2001/XMLSchema#string

William E Winter

http://www.w3.org/2001/XMLSchema#string

William P McGuire

http://www.w3.org/2001/XMLSchema#string

P304

3621-3627

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2006.10.2517

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17704411

http://www.w3.org/2001/XMLSchema#string

P921